N
Patient 1
AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.
| Seq | Brand | Generic | Manufacturer | Product code | Model | Catalog | Lot | PMA | 510(k) | Implant | Evaluated | Availability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARCHITECT CEA | CARCINOEMBRYONIC ANTIGEN | ABBOTT IRELAND | DHX | 07K68-27 | 88126FN00 | Y | Y |
| Sequence | Received | Treatment | Outcome |
|---|---|---|---|
| 1 | 2019-01-08 | 0 |
Patient 1
AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.
Patient 1
THE CUSTOMER REPORTED FALSE DECREASED ARCHITECT CEA RESULT FOR A RECENTLY DIAGNOSED COLON CANCER PATIENT. THE FOLLOWING CEA RESULTS WERE PROVIDED: 10/18: 6.6 NG/ML; 12/4: 4.8 NG/ML. THE CUSTOMER REPORTS NO TREATMENT WAS DONE. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.